Plandai Biotechnology, Inc. Commissions Stage 2 Of Senteeko Phytofare Factory

SEATTLE, WA--(Marketwired - April 01, 2014) - Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has completed and successfully optimized Stage 2 of its state-of-the-art production facility on the Senteeko Tea Estate in South Africa. Section 2 is the critical stage of the factory’s operations as it is in this section that the hydrodynamic sheering process takes place.

As previously disclosed, Plandaí’s unique extraction system uses live plant material and a combination of temperature and a unique wave of acoustic energy to release the living phytonutrients, rearranging the polyenes into a bio-compatible form. Stage 3 of the process then separates out the solids and any unnecessary elements, rendering pharmaceutical-grade, purified catechins in mainly nano-particle form. This Phytofare™ Catechin complex can then be sold “as is” as an ingredient for nutraceuticals and cosmetics or further processed by incorporating it into a Pheroid® emulsion. The Pheroid™ serves to protect the Phytofare™ as it passes through the GI tract or can enhance topical absorption.

Plandaí’s engineering team is currently working to complete Stage 3 and supporting infrastructures, including the boiler and computer automation system, which should brought online during April 2014. The final commissioning will take place this month as the company’s engineers and scientists fine-tune the equipment, train staff, and test the output for conformity with the product profile.

Chairman and Chief Executive Officer Roger Duffield commented, “Having successfully commissioned Stage 2, the one of a kind system is now complete. The magic of Phytofare involves unzipping the molecule to release the valuable phytonutrients, which we have now done for the first time on an industrial scale. Stage 3 should shortly come online once the computer system is in place and the final pieces are connected. It is exciting to see the culmination of over ten years of research and effort on the part of countless supporters.”

The first product Plandaí will bring to the market is Phytofare™ Catechin Complex, which includes the entire catechin profile derived from green tea. Stages 2 and 3 are also set up to process lemons, which will lead to the introduction of Phytofare™ Limonoid Glycoside Complex later in the year. Citrus bioflavonoids are highly regarded not only for treating cold and flu symptoms but also as a potent anti-inflammatory useful for soft-tissue injuries and sports recovery.

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company’s products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí’s ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.